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THE present investigation characterizes calcium iono-
phore (A-23187) induced peritoneal eicosanoid bio-
synthesis in the rat. Intraperitoneal injection of A-23187
(20 /,g/rat) stimulated marked biosynthesis of 6-keto-
PGFla (6-KPA), TxB2, LTC4 and LTB4, with no detectable
changes on levels of PGE2. Levels of all eicosanoids
decreased rapidly after a peak which was seen as early as
5 min. Enzyme markers of cellular contents of neutrophils
and mononuclear cells, MPO and NAG respectively,
decreased rapidly after ionophore injection; this was
followed by increases after 60min. Indomethacin, a
selective cyclooxygenase inhibitor, and zileuton and ICI
D-2138, two selective 5-1ipoxygenase inhibitors attenuated
prostaglandin and leukotriene pathways respectively. Oral
administration of zileuton (20 mg/kg, p.o.) inhibited LTB4
biosynthesis for up to 6 h suggesting a long duration of
pharmacological activity in the rats consistent with
its longer half-life. The rapid onset and the magnitude of
increases in levels of eicosanoids render the ionophore
induced peritoneal eicosanoid biosynthesis a useful model
to evaluate pharmacological profiles of inhibitors of
eicosanoid pathways in vivo.
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Introduction
Activation of cyclooxygenase (CO) and/or
lipoxyygenase (LO) pathways of arachidonic acid
metabolism generates lipid mediators with a
multitude of pharmacological activities; several of
these eicosanoids have been proposed to play a
major role in human inflammatory diseases such as
arthritis, asthma, psoriasis, ulcerative colitis and
shock. 1’2 These two pathways continue to be
targeted to develop selective inhibitors with which
to treat inflammatory diseases. Several animal
models have been developed to evaluate bio-
chemical eflqcacy and selectivity of inhibitors of
arachidonic acid metabolism using either a
non-immunologic or an immunologic stimulus.
All of these models involve the initiation of an
inflammatory response by the injection of a
pharmacological agent into an anatomical site that
allows measurement of indices of inflammation such
as oedema, vascular permeability, cellular infiltra-
tion and generation of inflammatory mediators. In
non-immunological models, materials such as
carrageenin, tragacanth, zymosan, thioglycollate,
calcium pyrophosphate, arachidonic acid, polymeric
sponge implants and ionophores such as A-23187
have all been used to elicit inflammatory responses
in diverse anatomical sites such as skin, dermis,
plantar region, peritoneal and pleural cavities. In
the immunological models, a specific antigen and
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antisera against it are injected into animals to elicit
inflammation in a desired anatomical site. The
indices of inflammation differ considerably in these
models, perhaps reflective of their cellular and
biochemical heterogeneity, and the nature of the
inflammatory stimulus.
3 As a result, the utility of a
given inflammation model is dictated by its
characteristics such as the time course of inflamma-
tion, nature of mediators and ease of measurement
of indices of inflammation.
As part of an ongoing effort to develop models
suitable for rapid evaluation of selective inhibitors
of CO and/or 5-LO pathways for their biochemical
efficacy, selectivity and duration of action, the
utility of calcium ionophore, A-23187 induced
peritoneal eicosanoid biosynthesis in the rat was
examined. In the present investigation, an evalu-
ation of selective inhibitors of CO and 5-LO
pathways in this model has been carried out.
Materials and Methods
Indomethacin, A-23187, hexadecyltrimethyl-
ammonium bromide (HTAB), 0-dianisidine 2HCl,
hydrogen peroxide and Tween-80 were purchased
from Sigma Chemical Co., St Louis, MO,
USA. Human polymorphonuclear myeloperoxidase
(MPO), bovine kidney N-acetyl-fl-D-glucosamini-
dase (NAG), p-nitrophenyl-2-acetamido-fl-D-gluco-
pyranoside were obtained from Calbiochem (San
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Diego, CA, USA). Selective 5-LO inhibitors,
zileuton (N-(1-benzo[b]-thien-2-yl)ethyl)-N-hydro-
xyurea;
4 ICI D-2138 (6-(3-fluoro-5-(4-methoxy-
3,4,5,6-tetrahydro-2H-pyran-4-yl)phenooxymethyl)
methyl-2-quinolone);s were synthesized in the
Chemistry Department of G. D. Searle & Co. Male
Sprague-Dawley rats (140-200 g; Charles River,
Portage, MD, USA) were used in all studies
described here. Rats were housed in an animal
vivarium with 12 h light and dark schedule. Rats
were fasted overnight for oral administration of test
compounds. The calcium ionophore, A-23187, was
dissolved in absolute alcohol to give a working
concentration of 2 mg/ml and kept at -4C until
use. On the day of the experiment, the alcoholic
solution of A-23187 was diluted into phosphate
buffered saline (PBS) to give a final concentration
of 20/,g/ml, just prior to intraperitoneal (i.p.)
injection. Indomethacin was dissolved in water with
the addition of 1N NaOH (final pH 7.4). Zileuton
and ICI D-2138 were administered as suspensions
in 0.5% methocel and 0.025% Tween-80. All drugs
were administered in a volume of 0.5 ml/rat and
appropriate vehicle controls were included in each
experiment. In additional experiments, protein
contents in lavage samples were determined by
Lowry’s method and cell counts were performed
using methods described in Diff-Quick Staining kit
(Baxter).
Induction of eicosanoid biosynthesis: Groups of rats (n
6- 8/treatment) were administered vehicle or test
compounds (p.o.) and at selected times injected
with A-23187 solution (20 /.tg/rat in 1 ml of PBS,
i.p.) or PBS with 1% alcohol. Rats were killed at
selected times by exposure to CO. followed by i.p.
injection of 20 ml of ice-cold saline. Peritoneal
contents were well mixed and 5 ml lavage samples
were collected from each rat. In additional
experiments, rats were injected were either saline or
A-23187 180min after an initial injection of
A-23187 and rats were sacrificed 15 min after the
second injection. The lavage samples were
centrifuged at 32000 x g (20min) and super-
natants used in eicosanoid assays by enzyme-
linked immunosorbent (EIA) assay protocols
(Cayman Chemicals, Ann Arbor, MI, USA). Levels
of thromboxane B2 (TxB2) 6-keto-prostaglandin-
FI= (6-KPA), prostaglandin E2 (PGE2) leukotrienes
(LT) B4 and C4 were measured as indices of
eicosanoid biosynthesis in lavage supernatants. The
pellets were used in MPO and NAG assays as
described below.
MPO andNAG assays: Cell pellets were disrupted by
sonification in 3 ml of 50 mM potassium phosphate
buffer (pH 6.0), centrifuged (32 000 x g, 20 min)
and supernatants were discarded. Cell pellets were
re-extracted into potassium phosphate buffer (50
mM, pH 6.0) with 0.5% HTAB, freeze thawed three
times and centrifuged to collect supernatants which
were used in MPO or NAG assays as per methods
described earlier6,v and adapted to a 96-well plate
format. Briefly, 7 #1 of unknowns or human
neutrophil MPO standards were added to a 96-well
plate. The utility of measurements of MPO and
NAG as enzyme markers for neutrophils
6 and
mononuclear cellsv respectively is well documented.
Results
Initially, the authors attempted to define the time
course of eicosanoid production and cellular
changes following the injection of 20#g of
A-23187/rat. In vehicle treated rats, levels of
eicosanoids remained in the range 100-500 pg/ml.
Levels of LTB4, LTC4, TxB2 and 6-KPA had
rapidly increased by 5 min, followed by a rapid
decline. The peak levels of eicosanoids represented
10- to 100-fold increases over the baseline levels
(Fig. 1). No significant increases in levels of PGE2
were seen at any time point (data not shown).
Levels ofMPO and NAG decreased dramatically at
the first time point sampled; this was followed by
increases between 60 and 300 min. In the control
group, peritoneal lavage samples contained mostly
neutrophils and a few mononuclear cells. Thirty
min after ionophore injection, very few intact
neutro-phils and mononuclear cells were seen.
However, by 180 min lavage samples contained
significant neutrophils and mononuclear cells
(Table 1). Thus measurements of enzyme markers
were corroborated by cell counts (Table 1 and
Fig. 1). The changes in protein contents in lavage
samples were less pronounced than changes in
levels of enzyme markers (protein in g/ml,
mean _+ S.E.M. (n 6); saline, 1.03 _+ 0.11 iono-
phore (15 rain), 1.62 _+ 0.16; ionophore (30 rain),
1.52 0.19; ionophore (60 min), 2.01 ___
0.13;
ionophore (120min), 1.53 +_ 0.1; and ionophore
(180 min), 1.83 0.23).
Interestingly, the second phase of increase in
levels of MPO and NAG was not associated with
any substantial eicosanoid biosynthesis. It was
reasoned that a depletion of A-23187 may have
contributed to a minimal eicosanoid biosynthesis at
these later times. When a second injection of
A-23187 was given 180 min after an initial injection
of A-23187, there were substantial increases in
levels of eicosanoids (Table 2) suggesting that the
incoming cells are capable of synthesizing eico-
sanoids in response to A-23187.
For evaluation of drug effects, rats were orally
administered selected doses of indomethacin or
zileuton 60min before i.p. administration of
A-23187 and lavage samples were collected 15 min
after A-23187 injection. Levels of 6-KPA and LTB4
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FIG.1. Upper panel--A-23187 induced eicosanoid biosynthesis in rat peritoneum. Male SD rats (n 6-8/treatment) were injected (i.p.) with 20 #g of
A-23187 in ml of PBS. At selected times thereafter, rats were sacrificed, injected (i.p.) with 20 ml of ice-cold PBS and lavage samples were withdrawn.
Values represent mean _
S.E.M. Eicosanoid levels between 5 and 120 min were significantly elevated compared with vehicle treated (zero-time) group
(one-way ANOVA followed by Dunnett’s test) Lower panel--*p < 0.05 vs vehicle-treated group (zero time; one-way ANOVA followed by Dunnett’s
test).
were used as indices of CO or 5-LO activity in vivo.
Indomethacin attenuated A-23187 induced increases
in 6-KPA levels without affecting levels of LTB4.
In contrast, zileuton, a selective 5-LO inhibitor,
attenuated leukotriene biosynthesis is a dose-
dependent manner without inhibiting levels of the
CO product, 6-KPA (Fig. 2). Similar to zileuton,
1CI D-2138 also selectively attenuated biosynthesis
of leukotriene B4. With a view to determining the
utility of this model to define dynamics of inhibition
of eicosanoid biosynthesis in vivo, rats were
challenged with A-23187 for 15 min at selected time
points after oral administration of zileuton (20
mg/kg, p.o.) and levels of LTB4 and 6-KPA were
measured in lavage samples. LTB4 levels were
maximally suppressed as early as 30min after
zileuton administration; this was followed by
Table 2. Effect of repeated A-23187 injection on eicosanoid
biosynthesis
Treatment 6- Keto-PG F1 LTB4
(ng/ml)* (ng/ml)*
Vehicle 0.12 _+ 0.03 0.01 _+ 0.004
Table 1. Effect of intraperitoneal injection of A-23187 on
cellular composition of peritoneal lavage samples
Treatment Neutrophils Macrophages Lymphocytes
Saline 142 _+ 7 30 _+ 3 29 _
8
A-23187 (30 min) <10 5 _+ 2 22 +_ 7
A-23187 (180min) 120_+ 14 66 _+ 13 8_+ 3
500/1 of lavage samples were used in a Cytospin (600 x g, 10
min) followed by fixation and staining (H & E stain) as per
protocols described in Diff-Quik Stain Set (Baxter Health Corp.).
Two hundred cells were counted and results are presented
as mean -I- S.E.M. (n 4-6).
A-23187 20.5 -t- 6.9* 14.9 -t- 4.2*
(20/g/rat" 15 min)
A-23187 (180 min) 0.20 _+ 0.02 0.03 _+ 0.01
+ Vehicle (15 min)
A-23187 (180 min) 24.0 _+ 4.7** 10.1 -I- 2.4**
+A-23187 (15 min)
Male SD rats (n 6/group) were injected with saline containing
1% alcohol (vehicle) or A-23187 in saline and sacrificed at times
indicated above. Additional groups of mice were injected with
A-23187 3h before second injection of either vehicle or
A-23187 and sacrificed 15 min later. *Values represent
mean -I- S.E.M.
**p < 0.001 vs vehicle or A-23187 + vehicle group.
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FIG.2. Effects of oral administration of indomethacin (0), ICI D-2138 (V) or zileuton (V) on A-23187 induced eicosanoid biosynthesis in vivo. Male
SD rats (n 6-8/treatment, fasted overnight) were administered indomethacin, zileuton or appropriate vehicle orally 60 min before i.p. injection of
20/xg of A-23187 in ml of PBS. Fifteen min following A-23187 injection, 20 ml of ice-cold PBS was injected (i.p.) and lavage samples were
collected. Values represent mean ___
S.E.M. *p < 0.05 vs A-23187 treated group (one-way analysis of variance followed by Neuman-Keuls test).
gradual increases 6 h post administration. During
the entire time course, there were no changes in
levels of 6-KPA (Fig. 3). Orally administered
indomethacin or zileuton did not affect ionophore
induced changes in MPO despite profound
inhibitory effects on mediator biosynthesis (MPO
levels, mean +_ S.E.M., n 6-8; saline 118 19;
ionophore (30 min) 8.0 -b 1.4; ionophore (180 rnin)
147 __+ 38; indomethacin (1 mg/kg), 119 _--b 25;
indornethacin (5 mg/kg), 139 _-q-25; zileuton (5
mg/kg), 152 __+ 39; and zileuton (20 mg/kg),
127 _--+- 19; drugs were given 30min before
ionophore injection). A similar profile was
observed forNAG levels as well (data not shown).
In addition to eicosanoid biosynthesis, A-23187
injected animals exhibited considerable writhing
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FIG.3. Time course of inhibition of eicosanoid biosynthesis following oral administration of zileuton (20 mg/kg, p.o.). Male SD rats (n 6-8/treatment,
fasted overnight) were administered zileuton or appropriate vehicle orally. At selected times thereafter, rats were injected with A-23187 (Iono) (20/xg
in ml of PBS). Fifteen min following A-23187 injection, 20 ml of ice-cold PBS was injected (i.p.) and lavage samples were collected. Values represent
mean -i- S.E.M. *p < 0.05 vscontrol (Con) group; **p < 0.05 vsA-23187 treated group (one-way analysis of variance followed by Neuman-Keuls test).
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response that was attenuated by pretreatment with
indomethacin, but not by zileuton or ICI D-2138
(data not shown). These observations suggest a role
for eicosanoids in initiating the writhing response,
consistent with earlier reports.
9
Discussion
Several investigators have characterized eicosa-
noid biosynthesis upon ionophore stimulation from
a variety of cell types in vitro.
9-11 Subsequently the
concept of ionophore induced eicosanoid biosyn-
thesis was used in the evaluation of inhibitors of
arachidonic acid metabolism in which whole blood
from rodents and humans was challenged ex vivo
with A-23187.4’12-1s In contrast, very few studies
used A-23187 in vivo.9’6’7 Although ex vivo
ionophore stimulation of whole blood is widely
used for pharmacological evaluation of 5-LO/CO
inhibitors, the presence of the inhibitor(s) in the
blood in appropriate levels is a prerequisite for
efficacy in this model. Unlike amphiphilic in-
hibitors, lipophilic inhibitors of arachidonate
metabolism are likely to be sequestered into tissue
sites and ex vivo eicosanoid production in blood may
not reflect their in vivo activity under these
conditions.
8 In order to evaluate effects of
(lipophilic) inhibitors of arachidonic acid, ideally,
arachidonic metabolism should be elicited in
tissue(s) in which eicosanoid biosynthesis is mini-
mally dependent on infiltrating cells. These issues
led us to examine ionophore induced eicosanoid
production in the rat peritoneal cavity as a facile
means of evaluating inhibitors of eicosanoid
metabolism in vivo. In the present investigation i.p.
treatment of A-23187 resulted in rapid biosynthesis
of both CO and 5-LO products, namely 6-KPA and
TxB2, and LTB4 and LTC4. In contrast to changes
in mediator biosynthesis, levels ofMPO and NAG,
which were enzyme markers of neutrophil and
mononuclear cells, decreased rapidly upon iono-
phore injection followed by increases at later time
points, by which time eicosanoid levels tended to
decrease. The initial phase of decline in levels of
these two enzymes may reflect the release of
intracellular granular enzymes upon activation with
ionophore coincident with cellular metabolic
activity and enhanced eicosanoid biosynthesis. The
second phase of increase in levels of MPO and
NAG may reflect influx of ceils containing these
enzymes into the peritoneal cavity in response to
generation of chemotactic and/or chemoattractant
mediators accompanied by changes in the vascular
permeability within the peritoneal milieu. Differ-
ential cell counts of lavage fluids support the MPO
and NAG estimates. The minimal cellular influx
within the first hour of ionophore administration
and a rapid onset of eicosanoid biosynthesis suggest
that resident peritoneal cells are the principal source
of eicosanoids in this inflammatory response.
Following the time course experiments with
A-23187, effects of inhibitors of eicosanoid
biosynthesis were examined with 15 min of A-23187
treatment as an end point. Although levels of
eicosanoids were declining, this end point proved
practical allowing ease of drug administration and
collection of lavage samples. Indomethacin or
zileuton and ICI D-2138 markedly attenuated
prostaglandin or leukotriene pathways respectively.
These results are consistent with their enzyme
specificity established in vitro and in vivo. 4,s Despite
marked effects on eicosanoid biosynthesis, in-
domethacin or zileuton failed to attenuate A-23187
induced changes in MPO or NAG. These results
suggest that products of arachidonate pathways by
CO or 5-LO enzyme are minimally important in
cellular infiltration in this model. These results are
at variance with inhibitory effects of indomethacin
and zileuton on cellular influx reported in other
models4’7 and further studies are needed to
delineate these differences.
With a view to studying dynamics of inhibition
of arachidonic acid metabolism, the time course of
inhibition of leukotriene B4 biosynthesis was
examined following oral administration of zileuton.
Significant attenuation of leukotriene B4 biosynth-
esis was noted as early as 30 min and lasted beyond
3h. These pharmocodynamic results are in
agreement with a half-life of 2.3 h and tma (time to
reach peak levels) of 15-30min from direct
measurements of zileuton levels in the rat.4 These
results clearly document the utility of this model in
defining pharmocodynamic effects of inhibitors of
eicosanoid metabolism.
Although immunological models of inflamma-
tion such as reverse passive Arthus reaction in the
peritoneal or pleural cavities provide useful means
of eliciting leukotriene biosynthesis, these responses
are strongly influenced by doses of antigens and
antibodies, and the requirement of high titre for
the antisera. 19 In contrast, non-immunological
methods such as injection of carrageenin, zymosan
or arachidonic acid provide more attractive means
of eliciting eicosanoid biosynthesis in vivo. Arach-
idonic acid administration elicits predominantly
prostaglandin biosynthesis with smaller increases in
5-LO metabolites in vivo. In contract, zymosan
administration results in rapid increases in prosta-
glandins and leukotrienes. The leukotriene produc-
tion in this model is dependent on influx of
phagocytic cells.8 Agents interfering with cellular
trafficking can attenuate eicosanoid biosynthesis in
response to injected zymosan despite a lack of direct
effects on CO and/or 5-LO enzymes. The time
course of A-23187 induced peritoneal eicosanoid
biosynthesis indicates a minimal role for infiltrating
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cells. The magnitude of increases in levels and rapid
onset of biosynthesis of eicosanoids permit
pharmacological manipulation by test compounds
allowing determination of selectivity, potency and
finally duration of action in vivo. These attributes
render A-23187 mediated eicosanoid biosynthesis a
rapid means of characterizing inhibitors of
arachidonic acid metabolism in vivo.
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